IgG-based Antibody Drug Conjugates (ADCs), are a highly promising format for the development of new cancer therapies. The biggest challenge with these constructs is that it is often necessary to dose very close to the Maximum Tolerated Dose giving these compounds a very narrow Therapeutic Index.
Our goal is to leverage the advantages of the Humabody® approach and Crescendo’s expertise in engineering multi-specific products – including tailored half-life extension – to create therapies with superior attributes compared to ADCs. Crescendo is the pioneer of Humabody Drug Conjugates (HDCs).
Watch this short animation below to see the therapeutic benefits of Humabodies over conventional antibodies
The Company has partnerships with several providers of next generation payloads that are focused on developing the ideal combination of size and payload, providing rapid tissue penetration with a specific, tailored serum half-life.
Humabody® is a registered trademark of Crescendo Biologics Ltd.